Значимость некоторых лейкоцитарных индексов у пациентов с сахарным диабетом 2-го типа, перенесших новую коронавирусную инфекцию

Одним из механизмов развития сахарного диабета 2-го типа является хроническое низкоинтенсивное воспаление. С целью объективизации данного процесса используются некоторые лейкоцитарные индексы (отношение нейтрофилов к лимфоцитам – NLR, отношение тромбоцитов к лимфоцитам – PLR, отношение лимфоцитов к моноцитам – LMR, отношение моноцитов к лимфоцитам – MLR, а также индекс системного иммунного воспаления SII (рассчитывается с учетом нейтрофилов, лимфоцитов, тромбоцитов) с учетом наличия у больных с сахарным диабетом как микрососудистых, так и макрососудистых поздних оосложнений. Новая коронавирусная инфекция значимо увеличивает процесс воспаления, при этом многие лейкоцитарные индексы являются прогностическими маркерами исхода заболевания. В статье приведены последние данные о значимости маркеров воспаления у мультиморбидных пациентов при наличии новой коронавирусной инфекции. Сделан акцент на то, что данные об изучении лейкоцитарных индексов у больных с сахарным диабетом, перенесших новую коронавирусную инфекцию, единичны, а информация о применении такого простого инструмента изучения воспаления, как лейкоцитарные индексы в оценке постковидных нарушений у больных с сахарным диабетом, отсутствует. Приведены собственные данные. Сделан вывод о том, что изучение воспаления у больных с СД 2-го типа и постковидным синдромом с использованием лейкоцитарных индексов представляет большой интерес.

1. Климонтов ВВ, Тян НВ, Фазуллина ОН, Мякина НЕ, Лыков АП, Коненков ВИ. Клинические и метаболические факторы, ассоциированные с хроническим воспалением низкой интенсивности, у больных сахарным диабетом 2-го типа. Сахарный диабет. 2016;19(4):295–202. https://doi.org/10.14341/DM7928.

2. Мокашева ЕН, Мокашева ЕН. Лейкоцитарные индексы у пациентов терапевтического и хирургического профиля. Научное обозрение. Медицинские науки. 2024;(3):24–29. https://doi.org/10.17513/srms.1400.

3. Maamar M, Artime A, Pariente E, Fierro P, Ruiz Y, Gutiérrez S et al. PostCOVID-19 syndrome, low-grade inflammation and inflammatory markers: a cross-sectional study. Curr Med Res Opin. 2022;38(6):901–909. https://doi.org/10.1080/03007995.2022.2042991.

4. Baluku JB, Nalwanga R, Kazibwe A, Olum R, Nuwagira E, Mugenyi N et al. Association between biomarkers of inflammation and dyslipidemia in drug resistant tuberculosis in Uganda. Lipids Health Dis. 2024;23(1):65. https://doi.org/10.1186/s12944-024-02063-7.

5. Chen HL, Wu C, Cao L, Wang R, Zhang TY, He Z. The association between the neutrophil-to-lymphocyte ratio and type 2 diabetes mellitus: a crosssectional study. BMC Endocr Disord. 2024;24(1):107. https://doi.org/10.1186/s12902-024-01637-x.

6. Zhang Y, Liu H. Correlation between insulin resistance and the rate of neutrophils-lymphocytes, monocytes-lymphocytes, plateletslymphocytes in type 2 diabetic patients. BMC Endocr Disord. 2024;24(1):42. https://doi.org/10.1186/s12902-024-01564-x.

7. Ghasempour Dabaghi G, Rabiee Rad M, Mortaheb M, Darouei B, AmaniBeni R, Mazaheri-Tehrani S et al. The Neutrophil-to-Lymphocyte Ratio Predicts Cardiovascular Outcomes in Patients With Diabetes: A Systematic Review and Meta-Analysis. Cardiol Rev. 2025;33(3):202–211. https://doi.org/10.1097/CRD.0000000000000820.

8. Chen G, Che L, Lai M, Wei T, Chen C, Zhu P, Ran J. Association of neutrophillymphocyte ratio with all-cause and cardiovascular mortality in US adults with diabetes and prediabetes: a prospective cohort study. BMC Endocr Disord. 2024;24(1):64. https://doi.org/10.1186/s12902-024-01592-7.

9. Hoes LLF, Riksen NP, Geleijnse JM, de Groot MCH, T van der Schouw Y, Visseren FLJ, Koopal C. Relationship of neutrophil-to-lymphocyte ratio, in addition to C-reactive protein, with cardiovascular events in patients with type 2 diabetes. Diabetes Res Clin Pract. 2024;213:111727. https://doi.org/10.1016/j.diabres.2024.111727.

10. Gong Y, Wang L, Li Q, Wang M, Luan R, Gao F, Hu L et al. Evaluating neutrophil-lymphocyte ratio, systemic immune-inflammation index, and systemic inflammation response index for diagnosing and predicting progression in diabetic retinopathy: a cross-sectional and longitudinal study. BMC Ophthalmol. 2025;25(1):398. https://doi.org/10.1186/s12886-025-04222-5.

11. Li J, Wang X, Jia W, Wang K, Wang W, Diao W et al. Association of the systemic immuno-inflammation index, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio with diabetic microvascular complications. Front Endocrinol. 2024;15:1367376. https://doi.org/10.3389/fendo.2024.1367376.

12. Yang X, Shi Y, Zhang H, Huang L, Zhang J, Min J, Chen L. Association between neutrophil-to-lymphocyte ratio and left ventricular diastolic dysfunction in patients with type 2 diabetes mellitus. Front Endocrinol. 2025;15:1499713. https://doi.org/10.3389/fendo.2024.1499713.

13. Joshi A, Bhambhani A, Barure R, Gonuguntla S, Sarathi V, Attia AM et al. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as markers of stable ischemic heart disease in diabetic patients: An observational study. Medicine. 2023;102(5):e32735. https://doi.org/10.1097/MD.0000000000032735.

14. Alfhili MA, Alsughayyir J, Basudan AM, Alsubki R, Alqahtani S, Awan ZA et al. Monocyte-Lymphocyte Ratio and Dysglycemia: A Retrospective, CrossSectional Study of the Saudi Population. Healthcare. 2022;10(11):2289. https://doi.org/10.3390/healthcare10112289.

15. Li H, Li Y, Guo W, Liu X, Wang Y, Zeng T, Kong W. Monocyte-lymphocyte ratio predicts cardiovascular diseases death in individuals with type 2 diabetes. J Diabetes Investig. 2025;16(1):137–145. https://doi.org/10.1111/jdi.14329.

16. Wu Y, Xiang HJ, Yuan M. Association of monocyte-lymphocyte ratio and myocardial infarction in the U.S. population with diabetes. Front Cardiovasc Med. 2024;11:1432838. https://doi.org/10.3389/fcvm.2024.1432838

17. Huang Q, Wu H, Wo M, Ma J, Fei X, Song Y. Monocyte-lymphocyte ratio is a valuable predictor for diabetic nephropathy in patients with type 2 diabetes. Medicine. 2020;99(19):e20190. https://doi.org/10.1097/MD.0000000000020190.

18. Kocak MZ, Aktas G, Duman TT, Atak BM, Kurtkulagi O, Tekce H et al. Monocyte lymphocyte ratio As a predictor of Diabetic Kidney Injury in type 2 Diabetes mellitus; The MADKID Study. J Diabetes Metab Disord. 2020;19(2):997–1002. https://doi.org/10.1007/s40200-020-00595-0.

19. Wang H, Guo Z, Xu Y. Association of monocyte-lymphocyte ratio and proliferative diabetic retinopathy in the U.S. population with type 2 diabetes. J Transl Med. 2022;20(1):219. https://doi.org/10.1186/s12967-022-03425-4.

20. Wang L, Gao J, Liu B, Fu Y, Yao Z, Guo S et al. The association between lymphocyte-to-monocyte ratio and all-cause mortality in obese hypertensive patients with diabetes and without diabetes: results from the cohort study of NHANES 2001-2018. Front Endocrinol. 2024;15:1387272. https://doi.org/10.3389/fendo.2024.1387272.

21. Li J, Zhao S, Zhang X, Fan M, Wan J, Lin R et al. Association of Systemic Inflammatory Response Index with the cardiometabolic multimorbidity among US adults: A population-based study. Brain Circ. 2025;11(1):39–47. https://doi.org/0.4103/bc.bc_32_24.

22. Patro S, Choudhary A, Sharma V, Mahajan A, Sahoo D, Pattnaik SS. Evaluating Platelet-to-Lymphocyte Ratio and Systemic ImmuneInflammation Index as Distinctive Biomarkers in Type 2 Diabetes Mellitus Patients With and Without Proteinuria: A Retrospective Study. Cureus. 2025;17(2):e79348. https://doi.org/10.7759/cureus.79348.

23. Gosav EM, Tanase DM, Ouatu A, Buliga-Finis ON, Popescu D, Dascalu CG et al. The Role of Neutrophil-to-Lymphocyte Ratio and Platelet-toLymphocyte Ratio in Predicting Atrial Fibrillation and Its Comorbidities. Life. 2025;15(6):960. https://doi.org/10.3390/life15060960.

24. Gao Y, Lu RX, Tang Y, Yang XY, Meng H, Zhao CL et al. Systemic immuneinflammation index, neutrophil-to-lymphocyte ratio, and platelet-tolymphocyte ratio in patients with type 2 diabetes at different stages of diabetic retinopathy. Int J Ophthalmol. 2024;17(5):877–882. https://doi.org/10.18240/ijo.2024.05.12.

25. Song Y, Lin Z, He J, Cui K, Song C, Zhang R et al. Association of platelet-tolymphocyte ratio levels with the risk of cardiac adverse events in people with type 2 diabetes undergoing percutaneous coronary intervention: A large-scale prospective cohort study. Diabetes Metab Syndr. 2024;18(3):102987. https://doi.org/10.1016/j.dsx.2024.102987.

26. Manaças LRA, Amorim RLO, Aguila A, Novo PC, Badin RC. Evaluation of hematological changes and immune response biomarkers as a prognostic factor in critical patients with COVID-19. PLoS ONE. 2024;19(2):e0297490. https://doi.org/10.1371/journal.pone.0297490.

27. Yılmaz A, Taşkın Ö, Demir U, Soylu VG. Predictive Role of Biomarkers in COVID-19 Mortality. Cureus. 2023;15(1):e34173. https://doi.org/10.7759/cureus.34173.

28. Ramos-Peñafiel CO, Santos-González B, Flores-López EN, Galván-Flores F, Hernández-Vázquez L, Santoyo-Sánchez A et al. Usefulness of the neutrophil-to-lymphocyte, monocyte-to-lymphocyte and lymphocyte-toplatelet ratios for the prognosis of COVID-19-associated complications. Gac Med Mex. 2020;156(5):405–411. https://doi.org/10.24875/GMM.M20000428.

29. Ghobadi H, Mohammadshahi J, Javaheri N, Fouladi N, Mirzazadeh Y, Aslani MR. Role of leukocytes and systemic inflammation indexes (NLR, PLR, MLP, dNLR, NLPR, AISI, SIR-I, and SII) on admission predicts inhospital mortality in non-elderly and elderly COVID-19 patients. Front Med. 2022;9:916453. https://doi.org/10.3389/fmed.2022.916453.

30. Li J, Zhang Y, Wu R, Ma G, Sheng L, Feng Y et al. Evaluation of Inflammatory Markers in Patients with COVID-19 Combined with Type 2 Diabetes Mellitus. Risk Manag Healthc Policy. 2024;17:2535–2545. https://doi.org/10.2147/RMHP.S490281.

31. Dymicka-Piekarska V, Dorf J, Milewska A, Łukaszyk M, Kosidło JW, Kamińska J et al. Neutrophil/Lymphocyte Ratio (NLR) and Lymphocyte/Monocyte Ratio (LMR) – Risk of Death Inflammatory Biomarkers in Patients with COVID-19. J Inflamm Res. 2023;16:2209–2222. https://doi.org/10.2147/JIR.S409871.

32. Şener G, Bayrak T, Coşkun C, Bayrak A. Neutrophil Lymphocyte Ratio, Monocyte Lymphocyte Ratio, Platelet Lymphocyte Ratio in Covid-19 Patients. Clin Lab. 2022;68(3). https://doi.org/10.7754/Clin.Lab.2021.210639.

33. De Rop L, Bos DA, Stegeman I, Holtman G, Ochodo EA, Spijker R et al. Accuracy of routine laboratory tests to predict mortality and deterioration to severe or critical COVID-19 in people with SARS-CoV-2. Cochrane Database Syst Rev. 2024;8(8):CD015050. https://doi.org/10.1002/14651858.CD015050.pub2.

34. Ben S, Gao F, Xu Z, Zhang R, Zhang X, Wang N et al. The role of hematological parameters in asymptomatic and non-severe cases of Omicron variant infection. Virol J. 2024;21(1):143. https://doi.org/10.1186/s12985-024-02414-x.

35. Briciu V, Leucuta DC, Muntean M, Radulescu A, Cismaru C, Topan A et al. Differences in the inflammatory response and outcome among hospitalized patients during different waves of the COVID-19 pandemic. Front Immunol. 2025;16:1545181. https://doi.org/10.3389/fimmu.2025.1545181.

36. Fors M, Ballaz S, Ramírez H, Mora FX, Pulgar-Sánchez M, Chamorro K et al. Sex-Dependent Performance of the Neutrophil-to-Lymphocyte, Monocyteto-Lymphocyte, Platelet-to-Lymphocyte and Mean Platelet Volume-toPlatelet Ratios in Discriminating COVID-19 Severity. Front Cardiovasc Med. 2022;9:822556. https://doi.org/10.3389/fcvm.2022.822556.

37. Keskin M, Burcak Polat S, Ateş I, Izdeş S, Rahmet Güner H, Topaloğlu O et al. Are neutrophil-to-lymphocyte ratios and large unstained cells different in hospitalized COVID-19 PCR-positive patients with and without diabetes mellitus? Eur Rev Med Pharmacol Sci. 2022;26(16):5963–5970. https://doi.org/10.26355/eurrev_202208_29537.

38. Liu G, Zhang S, Hu H, Liu T, Huang J. The role of neutrophil-lymphocyte ratio and lymphocyte-monocyte ratio in the prognosis of type 2 diabetics with COVID-19. Scott Med J. 2020;65(4):154–160. https://doi.org/10.1177/0036933020953516.

39. Danila AI, Cioca F, Gadde ST, Daruvuri SP, Timar R, Hogea E. Prognostic Utility of dNLR, ALRI, APRI, and SII in COVID-19 Patients with Diabetes: A Cross-Sectional Study. Diagnostics. 2024;14(15):1685. https://doi.org/10.3390/diagnostics14151685.

40. Jan MI, Anwar Khan R, Khan N, Iftikhar SM, Ali S, Khan MI et al. Modulation in serum and hematological parameters as a prognostic indicator of COVID-19 infection in hypertension, diabetes mellitus, and different cardiovascular diseases. Front Chem. 2024;12:1361082. https://doi.org/10.3389/fchem.2024.1361082.

41. Li J, Zhang Y, Wu R, Ma G, Sheng L, Feng Y et al. Evaluation of Inflammatory Markers in Patients with COVID-19 Combined with Type 2 Diabetes Mellitus. Risk Manag Healthc Policy. 2024;17:2535–2545. https://doi.org/10.2147/RMHP.S490281.

42. Oronsky B, Larson C, Hammond TC, Oronsky A, Kesari S, Lybeck M, Reid TR. A Review of Persistent Post-COVID Syndrome (PPCS). Clin Rev Allergy Immunol. 2023;64(1):66–74. https://doi.org/10.1007/s12016-021-08848-3.

43. Peghin M, Palese A, Venturini M, De Martino M, Gerussi V, Graziano E et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clin Microbiol Infect. 2021;27(10):1507–1513. https://doi.org/10.1016/j.cmi.2021.05.033.

44. Салухов ВВ, Арутюнов ГП, Тарловская ЕИ, Батлук ТИ, Башкинов РА, Самусь ИВ и др. Влияние нарушений углеводного обмена на ранние и отдаленные клинические исходы у пациентов с COVID-19 по данным регистров АКТИВ и АКТИВ 2. Проблемы эндокринологии. 2023;69(1):36–49. https://doi.org/10.14341/probl13175.

45. Садовский ИС, Круглова ОС, Савченко АА, Собко ЕА, Каспаров ЭВ, Демко ИВ, Борисов АГ. Комплексные показатели воспаления у больных с постковидным синдромом. Российский иммунологический журнал. 2022;26(1):77–86. https://doi.org/10.46235/1028-7221-1186-CII.